Abstract
All species require a rapid, systemic reply to pathogens in their environment. This response is known as the innate immune response and is characterized by de novo synthesis of mediators that directly or indirectly through phagocytosis remove and kill the pathogen. Innate immune responses have been preserved throughout evolution and have been studied in detail in organisms from the fruit fly Drosophila melanogaster to humans. In my laboratory, studies performed during the past 25 yr have focused on defining the molecular basis of innate immune responses to microbial pathogens. Specifically, we have used bacterial endotoxin (lipopolysaccharide) as a model stimulus to define how the innate immune system recognizes products of microbial pathogens and initiates responses to remove and/or kill such organisms. Such studies also serve as models to understand more fully the mechanisms underlying a serious human disease known as septic shock. This article discusses septic shock and its relationship to innate immunity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Deitch EA: Animal models of sepsis and shock: a review and lessons learned. Shock 1998;9: 1–11.
Zanetti G, Baumgartner JD, Glauser MP: Sepsis and septic shock. Schweiz Med Wochenschr 1997;127:489–499.
Thomas L: The Lives of a Cell. Notes of a Biology Watcher. New York, Viking, 1974.
Ferrero E, Goyert SM: Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14. Nuclei Acids Res 1988; 16:4173.
Wright SD Ramos RA, Tobias PS, et al.: CD14 serves as the cellular receptor for complexes of lipopolysaccharide with lipopolysacharide binding protein. Science 1990;249:1431–1433.
Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13: 437–457.
Schmike J, Mathison J, Morgiewicz J, Ulevitch RJ: Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998;95:13,875–13,880.
Pugin J, Kravchenko V, Le J-D, et al.: Cell activation medicated by glycosylphosphatidyli-nositol-anchored or transmembrane forms of CD14. Infect Immun 1908;66:1174–1180.
Lee J-D, Kravchenko V, Kirkland TN, et al.: GPI-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci USA 1993;90:9930–9934.
Lee JD, Kato K, Tobias PS, et al.: Transfection of CD 14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992; 175:1697–1705.
Hultmark D: Immune reactions in Drosophila and other insects: a model for innate immunity. TIG 1993;9:178–183.
Medzhitov R, Janeway CA, Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:295–298.
Kopp EB, Medzhitov R: The Tollreceptor family and control of innate immunity. Curr Opin Immunol 1999;11:13–18.
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity: Nature 1997;388: 394–397.
Rock FL, Hardiman G, Timans JC, et al.: A family of human receptors structurally related to Drosophila toll. Proc Natl Acad Sci USA 1998;95:588–593.
Chaudhary PM, Ferguson C, Nguyen V, et al.: Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multigene receptor family in humans. Blood 1998;91:4020–4027.
Kirschning CJ, Wesche H, Ayres TM, Rothe M: Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188: 2091–2097.
Yang RB, Mark MR, Gray A, et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395: 284–288.
Chow JC, Young DW, Golenbok DT, et al.: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10,689–10,692.
Schwandner R, Dziarski R, Wesche H, et al.: Reptidoglycanand lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem 1999; 274:17,406–17,409.
Yoshimura, A., Lien E, Ingalls RR, et al.: Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol 1999;163:1–5.
Williams MJ, Rodriguez A, Kimbrell DA, Eldon ED: The 18-wheeler mutation revealscomplex antibacterial gene regulation in Drosophila host defense. EMBO J 1997;16:6120–6130.
Lemaitre B, Nicolas E, Michaut L, et al.: The dorsovemtral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973–983.
Heine H, Kirschning CJ, Lien E, et al.: Cutting edge: cells that carry a null allele for Toll-like receptor 2 are capable of responding to endotox in. J. Immunol 1999;162:6971–6975.
Poltorak A, He X, Smirnova I, et al.: Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in TIr4 gene. Science 1998;282:2085–2088.
Qureshi ST, Lariviere L, Leveque G, et al.: Endotoxin-to lerant mice have mutations in Toll-like receptor 4 Tlr4. J Exp Med 1999;189: 615–625.
Vogel SN, Johnson D, Perera PY, et al.: Cutting edge: Functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant regative mutation. J Immunol 1999;12:5666–5670.
Hoshino K, Takeuchi O, Kawai T, et al.: Cuttingedge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysac-charide: evidence for TLR4 as the Lps gene product. J Immunol 1999;12:3749–3752.
Medzhitov R, Preston-Hurlbert P, Kopp E, et al.: MyD88 is an adaptor protein in the hToll/IL1 receptor family signaling pathways. Mol Cell 1998;2:253–258.
Auron PE: The interleukin-1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998;9:221–237.
Zhang FX, Kirschning CJ, Mancinelli R, et al.: Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human demal endothelial cells and mononuclear phagocytes. J Biol Chem 1999;274:7611–7614.
Wesche H, Gao X, Li X, et al.: IRAK-M is a novel member of the Pelle/Interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999;274: 19,403–19,410.
Li X, Commane M, Burns C, et al.: Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol 1999; 19:4643–4652.
Derijard B, Raingeaud J, Barrett T, et al.: Independent human MAP kinase signal transduction path-ways defined by MEK and MKK isoforms. Science 1995;267: 682–685.
Han J, Wang X, Jiang Y, et al.: Identification and characterization of a predominant isoform of human MKK3. FEBS Lett 1996;403: 19–22.
Han J, Lee J-D, Jiang Y, et al.: Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem 1996;271:2886–2891.
Li Z, Jiang Y, Ulevitch RJ, Han J: The primary structure of p38 gamma: a new member of p38 group of MAP kinase. Biochem Biophys Res Commun 1996;228: 334–340.
Han J, Jiang Y, Li Z, et al.: Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997;386: 296–299.
Han J, Lee J-D, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotox in and by penosmolarity in mammalian cells. Science 1994; 265:808–811.
Hambleton J, Weirstein SL, Lem L, DeFranco AL: Activation of c-Jun N-termiral kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA 1996;93:2774–2778.
Hambleton J, McMahon M. DeFranco AL: Activation of Ref-1 and mitogen-activated protein kinase in murine macrophares partially mimics lipopolys echaride-induced signaling events. J Exp Med 1995;182:147–154.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ulevitch, R.J. Molecular mechanisms of innate immunity. Immunol Res 21, 49–54 (2000). https://doi.org/10.1385/IR:21:2-3:49
Issue Date:
DOI: https://doi.org/10.1385/IR:21:2-3:49